drugset / Trial / NCT01205321

PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers

NCT01205321

Phase 1 Completed 19 enrolled Lantheus Biosciences Ltd.
RandomizedParallel-groupOpen-labelDiagnostic

Summary

Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.

Timeline

Start
2010-11
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-RM2 Diagnostic / imaging agent 28 ug Intravenous
Subject 68Ga-RM2 Diagnostic / imaging agent 140 mbq Intravenous

Indications

No indication recorded.